Tag Archives: Leland Gershell
Oppenheimer Thinks Acasti Pharma’s Stock is Going to Recover
In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on Acasti Pharma (ACST – Research Report), with a price target of $7.00. The company’s shares closed last Monday at $0.47, close to its 52-week low of
Oppenheimer Believes Corbus Pharmaceuticals (NASDAQ: CRBP) Won’t Stop Here
Oppenheimer analyst Leland Gershell assigned a Buy rating to Corbus Pharmaceuticals (CRBP – Research Report) today and set a price target of $28.00. The company’s shares closed last Monday at $8.14, close to its 52-week high of $8.66. According to
Oppenheimer Believes Acceleron Pharma (NASDAQ: XLRN) Still Has Room to Grow
Oppenheimer analyst Leland Gershell assigned a Buy rating to Acceleron Pharma (XLRN – Research Report) today and set a price target of $120.00. The company’s shares closed last Wednesday at $102.54, close to its 52-week high of $110.49. According to
Corbus Pharmaceuticals (CRBP) Receives a Buy from Oppenheimer
Oppenheimer analyst Leland Gershell maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) today and set a price target of $28.00. The company’s shares closed last Thursday at $7.97, close to its 52-week high of $8.66. According to
Amarin (AMRN) Receives a Hold from Oppenheimer
In a report released today, Leland Gershell from Oppenheimer maintained a Hold rating on Amarin (AMRN – Research Report). The company’s shares closed last Tuesday at $6.83, close to its 52-week low of $3.95. According to TipRanks.com, Gershell is a
Evofem Biosciences (EVFM) Received its Third Buy in a Row
After H.C. Wainwright and RBC Capital gave Evofem Biosciences (NASDAQ: EVFM) a Buy rating last month, the company received another Buy, this time from Oppenheimer. Analyst Leland Gershell assigned a Buy rating to Evofem Biosciences yesterday and set a price
